Adult stem cell transplantation combined with conventional therapy for the treatment of end-stage liver disease: a systematic review and meta-analysis

Stem Cell Research & Therapy

Xiang-Gen Wu¹  Chuan-Long Guo¹  Qi-Long Cao²  Jing Xu³  Guo-Hu Di³  Dian-Han Zhang³  Chen-Wei Zhu³  Chen-Hui Zhu³ 

[1] College of Chemical Engineering, Qingdao University of Science and Technology;Qingdao Haier Biotech Co. Ltd;School of Basic Medicine, Qingdao University;

关键词: End-stage liver disease;    Stem cell transplantation;    Conventional therapy;    Adult stem cells;    Liver function;   

DOI  :  10.1186/s13287-021-02625-x

来源: DOAJ

【 摘 要 】

Abstract End-stage liver disease (ESLD) is characterized by the deterioration of liver function and a subsequent high mortality rate. Studies have investigated the use of adult stem cells to treat ESLD. Here, a systematic review and meta-analysis was conducted to determine the efficacy of a combination therapy with adult stem cell transplantation and traditional medicine for treating ESLD. Four databases—including PubMed, Web of Science, Embase, and Cochrane Library—were investigated for studies published before January 31, 2021. The main outcome indicators were liver function index, model for end-stage liver disease (MELD) scores, and Child‒Turcotte‒Pugh (CTP) scores. Altogether, 1604 articles were retrieved, of which eight met the eligibility criteria; these studies included data for 579 patients with ESLD. Combination of adult stem cell transplantation with conventional medicine significantly improved its efficacy with respect to liver function index, CTP and MELD scores, but this effect gradually decreased over time. Moreover, a single injection of stem cells was more effective than two injections with respect to MELD and CTP scores and total bilirubin (TBIL) and albumin (ALB) levels, with no significant difference in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. With respect to the TBIL levels, patients receiving mononuclear cells (MNCs) experienced a significantly greater therapeutic effect—starting from twenty-four weeks after the treatment—whereas with respect to ALB levels, CD34+ autologous peripheral blood stem cells (CD34+ APBSCs) and MNCs had similar therapeutic effects. Severe complications associated with adult stem cell treatment were not observed. Although the benefits of combination therapy with respect to improving liver function were slightly better than those of the traditional treatment alone, they gradually decreased over time. Systematic review registration: PROSPERO registration number: CRD42021238576.

【 授权许可】

Unknown